Literature DB >> 24966987

A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.

Ranjit Nair1, Shereen Gheith2, Dan Popescu3, Nicole M Agostino3.   

Abstract

Lenalidomide belongs to a novel class of drugs called Immunomodulators which are now being used for the treatment of plasma cell dyscrasias with variable degrees of efficacy and toxicity. Though Second Primary Malignancies (SPM) have been a concern with its use, the benefits of the treatment outweigh the risks. The leukemogenic risk seems to be potentiated especially when combined with alkylating agents and the SPMs documented are predominantly myeloblastic. To date there are no reported cases of new lymphocytic leukemias in AL amyloidosis, regardless of whether undergone treatment or not. We present a case of AL amylodosis who was treated with lenalidomide and subsequently developed acute lymphoblastic leukemia.

Entities:  

Keywords:  AL amyloidosis; Second primary malignancy; acute lymphoblastic leukemia; lenalidomide

Mesh：

Substances：

Year:  2014        PMID： 24966987      PMCID： PMC4069899     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN： 1936-2625


  35 in total

1.  Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis.

Authors:  R Fonseca; S V Rajkumar; G J Ahmann; S M Jalal; J D Hoyer; M A Gertz; R A Kyle; P R Greipp; G W Dewald
Journal:  Leuk Lymphoma       Date:  2000-10

2.  Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH.

Authors:  Gienke R Boersma-Vreugdenhil; Ton Peeters; Bert J E G Bast; Henk M Lokhorst
Journal:  Blood       Date:  2003-02-15       Impact factor: 22.113

3.  Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.

Authors:  Vaishali Sanchorawala; Anthony C Shelton; Jerome B Zeldis; David C Seldin
Journal:  Am J Hematol       Date:  2013-05-30       Impact factor: 10.047

4.  Multiple myeloma and acute myelomonocytic leukemia.

Authors:  R A Kyle; R V Pierre; E D Bayrd
Journal:  N Engl J Med       Date:  1970-11-19       Impact factor: 91.245

5.  Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis.

Authors:  S R Hayman; R J Bailey; S M Jalal; G J Ahmann; A Dispenzieri; M A Gertz; P R Greipp; R A Kyle; M Q Lacy; S V Rajkumar; T E Witzig; J A Lust; R Fonseca
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

Review 6.  Chromosome translocations in multiple myeloma.

Authors:  P L Bergsagel; W M Kuehl
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

7.  Id4 is deregulated by a t(6;14)(p22;q32) chromosomal translocation in a B-cell lineage acute lymphoblastic leukemia.

Authors:  Mar Bellido; Anna Aventín; Adriana Lasa; Camino Estivill; Maria J Carnicer; Cristina Pons; Xavier Matías-Guiu; Ramón Bordes; Montserrat Baiget; Jorge Sierra; Josep F Nomdedéu
Journal:  Haematologica       Date:  2003-09       Impact factor: 9.941

8.  t(14;19)(q32;q13): a recurrent translocation in B-cell precursor acute lymphoblastic leukemia.

Authors:  Hazel M Robinson; Kerry E Taylor; G Reza Jalali; Kan Luk Cheung; Christine J Harrison; Anthony V Moorman
Journal:  Genes Chromosomes Cancer       Date:  2004-01       Impact factor: 5.006

9.  The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.

Authors:  Rafael Fonseca; Carina S Debes-Marun; Elisa B Picken; Gordon W Dewald; Sandra C Bryant; Jerry M Winkler; Emily Blood; Martin M Oken; Rafael Santana-Dávila; Natalia González-Paz; Robert A Kyle; Morie A Gertz; Angela Dispenzieri; Martha Q Lacy; Philip R Greipp
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

10.  Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms.

Authors:  C Dong; K Hemminki
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640
View more
  2 in total

1.  A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.

Authors:  Gaixiang Xu; Bo Wang; Min Yang; Wenbin Qian
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.

Authors:  Ahmad Alhuraiji; Kiran Naqvi; Yang O Huh; Coty Ho; Srdan Verstovsek; Prithviraj Bose
Journal:  Clin Case Rep       Date:  2017-12-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.